Corvas, Schering-Plough deal

Schering-Plough paid $1 million to extend until December 1996 its option to expand a 1994 research agreement between the companies. The option covers a program to develop and commercialize inhibitors of coagulation Factor Xa, an enzyme in the blood-clotting process. ...